{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704103,0.0004023284,0.0006114789,0.00008841295,0.000472889,0.00004699292,0.001073641,0.0004025481,0.00008022862],"category_scores_gemma":[0.0007000043,0.0002358646,0.0001233162,0.0001816194,0.0006675378,0.00002229534,0.0007544854,0.0005089352,0.000003094219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002519934,"about_ca_system_score_gemma":0.000829522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00149458,"about_ca_topic_score_gemma":0.01378081,"domain_scores_codex":[0.9972559,0.0004058643,0.0006680146,0.0007816053,0.0002942851,0.0005943478],"domain_scores_gemma":[0.9974871,0.0001221911,0.0007138692,0.001334284,0.0002015443,0.0001409914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004414432,0.003070624,0.02407406,0.0000926082,0.000380036,0.00008367751,0.003855504,0.0009190509,0.9259074,0.00001156978,0.003397693,0.03379331],"study_design_scores_gemma":[0.04897723,0.01385704,0.03949884,0.000269006,0.0003741093,0.00007662195,0.005140101,0.001465957,0.7891095,0.00006075189,0.09980402,0.001366799],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938735,0.001774764,0.00003098721,0.0009022313,0.001670267,0.001480902,0.0001277361,0.00002048319,0.0001190915],"genre_scores_gemma":[0.9974502,0.000270208,0.0003161992,0.0003980802,0.0005963633,0.0004019366,0.00001678338,0.00006157365,0.0004886522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1367979,"threshold_uncertainty_score":0.9618278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03309205630219511,"score_gpt":0.3685072594238245,"score_spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}